Clinical Trials
-
A Phase I Dose Escalation Study of Weekly SGN-35 Alone and in Combination With Gemcitabine in HL
Recruiting
-
A Pivotal Open-Label Trial of SGN-35 for Hodgkin Lymphoma
Recruiting
-
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
Recruiting
-
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
Recruiting
-
Phase II Poor Risk Diffuse Large B-cell Lymphoma (DLBCL) of Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) Followed by Matched Allogeneic Hematopoietic Transplantation as Consolidation to Autologous Hematopoietic Cell Transplantation (AHCT)
Recruiting
-
Phase III CHOP + Rituximab vs CHOP + Iodine-131 Monoclonal Anti-B1 Antibody for New Dx Foll NHL
Recruiting
-
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
Recruiting
-
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
Recruiting
-
A Phase 2 Open Label Trial of SGN-35 for Systemic Anaplastic Large Cell Lymphoma
Recruiting
-
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Second-Line Treatment of Patients With DLBCL
Recruiting
-
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Recruiting
-
Bone Marrow Grafting for Leukemia and Lymphoma
Recruiting
-
Clinical Trial of PXD101 in Patients With T-Cell Lymphomas
Recruiting
-
Ph II, Multicenter, Simon 2-Stage of R788 For Relapsed or Refractory T-Cell Lymphoma
Recruiting
-
Phase I/II of a CpG-Activated Whole Cell Vaccine Followed by Autologous “Immunotransplant” for MCL
Recruiting
-
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
Completed
-
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
No longer recruiting
-
Rituximab in Treating Patients With Hodgkin's Lymphoma
No longer recruiting
-
Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
No longer recruiting
-
Rituximab, Combination Chemotherapy, and Bortezomib in Treating Patients With Untreated Mantle Cell Lymphoma
No longer recruiting
-
Rituximab, Combination Chemotherapy, and Bortezomib in Treating Patients With Untreated Mantle Cell Lymphoma
No longer recruiting
-
Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Lymphoma
No longer recruiting
-
Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
Terminated
-
A Dose and Schedule Finding Trial With AMG 531 for CIT in Adults With Lymphoma
Completed
-
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
No longer recruiting
-
Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
No longer recruiting
-
Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma
No longer recruiting
-
Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma
No longer recruiting
-
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma
No longer recruiting
-
Phase I/II CPG 7909 + Local XRT in Recurrent Low-Grade Lymphomas
No longer recruiting
-
Study of SGN-40 (Anti-huCD40 mAb) in Patients With Relapsed Diffuse Large B-Cell Lymphoma
No longer recruiting
Help